Open
Actively Recruiting
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
About
Brief Summary
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.
Study Type
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Males and females aged 18 years and older
- Patients with known Alpha-1 Anti-trypsin deficiency (PiZZ)
- Be an existing member of the Alpha-1 Foundation Clinical Cohort (Alpha-1 Foundation Research Registry)
- Willingness to perform study procedures of Chest CT, blood biomarker determination, questionnaire completion, and lung function testing.
Exclusion Criteria:
- AATD non-PiZZ status, including carriers
- Pregnancy at the time of the screening visit
- COPD exacerbation or other pulmonary infection within 6 weeks of baseline visit
- Previous lung or liver transplantation or currently on the transplant list
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
22-000634
Category
Genetic and Rare Diseases
Principal Investigator
Contact
Location
- UCLA Westwood